Aripiprazole in bipolar depression

A pooled, post-hoc analysis by severity of core depressive symptoms

Michael E. Thase, Charles L. Bowden, Michael Nashat, James M. Eudicone, Ronald Marcus, Robert D. McQuade, Berit X. Carlson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective. This post-hoc analysis of pooled data from two similarly designed trials assessed the impact of aripiprazole monotherapy vs. placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder. Methods. Patients were classified as severely depressed (Bech-6 Total score > 15) or less severely depressed (Bech-6 Total score < 15). Efficacy was assessed by mean changes in Montgomery-Åsberg Depression Rating Scale (MADRS) Total and MADRS-6 subscale scores from baseline to endpoint using a mixed model repeated measures analysis. Results. A total of 133 patients (n = 62 on active aripiprazole) were classified as severely depressed and 612 patients (n 309 aripiprazole) as less severely depressed. At endpoint, the mean MADRS Total score reduction for severely depressed patients receiving aripiprazole compared with placebo was -19.4 vs. -15.4 (P = 0.14), whereas MADRS-6 subscale score reduction for patients receiving aripiprazole compared with placebo was -13.8 vs. -10.3 (P = 0.07). Adverse event profiles were similar between the two severity groups. Conclusions. Symptomatic improvements assessed here suggest that aripiprazole monotherapy at the doses studied may provide some improvements in core symptoms of depression in patients with bipolar I disorder who were more severely depressed.

Original languageEnglish (US)
Pages (from-to)121-131
Number of pages11
JournalInternational Journal of Psychiatry in Clinical Practice
Volume16
Issue number2
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Bipolar Disorder
Depression
Placebos
Aripiprazole

Keywords

  • Aripiprazole
  • Bipolar depression
  • Bipolar disorder
  • Efficacy
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Aripiprazole in bipolar depression : A pooled, post-hoc analysis by severity of core depressive symptoms. / Thase, Michael E.; Bowden, Charles L.; Nashat, Michael; Eudicone, James M.; Marcus, Ronald; McQuade, Robert D.; Carlson, Berit X.

In: International Journal of Psychiatry in Clinical Practice, Vol. 16, No. 2, 06.2012, p. 121-131.

Research output: Contribution to journalArticle

Thase, Michael E. ; Bowden, Charles L. ; Nashat, Michael ; Eudicone, James M. ; Marcus, Ronald ; McQuade, Robert D. ; Carlson, Berit X. / Aripiprazole in bipolar depression : A pooled, post-hoc analysis by severity of core depressive symptoms. In: International Journal of Psychiatry in Clinical Practice. 2012 ; Vol. 16, No. 2. pp. 121-131.
@article{a9124a7b1bc340c498d88d6411749666,
title = "Aripiprazole in bipolar depression: A pooled, post-hoc analysis by severity of core depressive symptoms",
abstract = "Objective. This post-hoc analysis of pooled data from two similarly designed trials assessed the impact of aripiprazole monotherapy vs. placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder. Methods. Patients were classified as severely depressed (Bech-6 Total score > 15) or less severely depressed (Bech-6 Total score < 15). Efficacy was assessed by mean changes in Montgomery-{\AA}sberg Depression Rating Scale (MADRS) Total and MADRS-6 subscale scores from baseline to endpoint using a mixed model repeated measures analysis. Results. A total of 133 patients (n = 62 on active aripiprazole) were classified as severely depressed and 612 patients (n 309 aripiprazole) as less severely depressed. At endpoint, the mean MADRS Total score reduction for severely depressed patients receiving aripiprazole compared with placebo was -19.4 vs. -15.4 (P = 0.14), whereas MADRS-6 subscale score reduction for patients receiving aripiprazole compared with placebo was -13.8 vs. -10.3 (P = 0.07). Adverse event profiles were similar between the two severity groups. Conclusions. Symptomatic improvements assessed here suggest that aripiprazole monotherapy at the doses studied may provide some improvements in core symptoms of depression in patients with bipolar I disorder who were more severely depressed.",
keywords = "Aripiprazole, Bipolar depression, Bipolar disorder, Efficacy, Tolerability",
author = "Thase, {Michael E.} and Bowden, {Charles L.} and Michael Nashat and Eudicone, {James M.} and Ronald Marcus and McQuade, {Robert D.} and Carlson, {Berit X.}",
year = "2012",
month = "6",
doi = "10.3109/13651501.2011.632680",
language = "English (US)",
volume = "16",
pages = "121--131",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Aripiprazole in bipolar depression

T2 - A pooled, post-hoc analysis by severity of core depressive symptoms

AU - Thase, Michael E.

AU - Bowden, Charles L.

AU - Nashat, Michael

AU - Eudicone, James M.

AU - Marcus, Ronald

AU - McQuade, Robert D.

AU - Carlson, Berit X.

PY - 2012/6

Y1 - 2012/6

N2 - Objective. This post-hoc analysis of pooled data from two similarly designed trials assessed the impact of aripiprazole monotherapy vs. placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder. Methods. Patients were classified as severely depressed (Bech-6 Total score > 15) or less severely depressed (Bech-6 Total score < 15). Efficacy was assessed by mean changes in Montgomery-Åsberg Depression Rating Scale (MADRS) Total and MADRS-6 subscale scores from baseline to endpoint using a mixed model repeated measures analysis. Results. A total of 133 patients (n = 62 on active aripiprazole) were classified as severely depressed and 612 patients (n 309 aripiprazole) as less severely depressed. At endpoint, the mean MADRS Total score reduction for severely depressed patients receiving aripiprazole compared with placebo was -19.4 vs. -15.4 (P = 0.14), whereas MADRS-6 subscale score reduction for patients receiving aripiprazole compared with placebo was -13.8 vs. -10.3 (P = 0.07). Adverse event profiles were similar between the two severity groups. Conclusions. Symptomatic improvements assessed here suggest that aripiprazole monotherapy at the doses studied may provide some improvements in core symptoms of depression in patients with bipolar I disorder who were more severely depressed.

AB - Objective. This post-hoc analysis of pooled data from two similarly designed trials assessed the impact of aripiprazole monotherapy vs. placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder. Methods. Patients were classified as severely depressed (Bech-6 Total score > 15) or less severely depressed (Bech-6 Total score < 15). Efficacy was assessed by mean changes in Montgomery-Åsberg Depression Rating Scale (MADRS) Total and MADRS-6 subscale scores from baseline to endpoint using a mixed model repeated measures analysis. Results. A total of 133 patients (n = 62 on active aripiprazole) were classified as severely depressed and 612 patients (n 309 aripiprazole) as less severely depressed. At endpoint, the mean MADRS Total score reduction for severely depressed patients receiving aripiprazole compared with placebo was -19.4 vs. -15.4 (P = 0.14), whereas MADRS-6 subscale score reduction for patients receiving aripiprazole compared with placebo was -13.8 vs. -10.3 (P = 0.07). Adverse event profiles were similar between the two severity groups. Conclusions. Symptomatic improvements assessed here suggest that aripiprazole monotherapy at the doses studied may provide some improvements in core symptoms of depression in patients with bipolar I disorder who were more severely depressed.

KW - Aripiprazole

KW - Bipolar depression

KW - Bipolar disorder

KW - Efficacy

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84860844540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860844540&partnerID=8YFLogxK

U2 - 10.3109/13651501.2011.632680

DO - 10.3109/13651501.2011.632680

M3 - Article

VL - 16

SP - 121

EP - 131

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 2

ER -